Alemtuzumab - Biologic Drug Details

✉ Email this page to a colleague

Summary for alemtuzumab

Tradenames:	2
High Confidence Patents:	7
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for alemtuzumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for alemtuzumab

Recent Clinical Trials for alemtuzumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Assistance Publique - Hôpitaux de Paris	Phase 2
City of Hope Medical Center	Phase 1
Neovii Biotech	Phase 2

See all alemtuzumab clinical trials

Recent Litigation for alemtuzumab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
AbbVie Inc. v. Hetero USA, Inc.	2023-11-20
Janssen Biotech, Inc. v. Amgen Inc.	2022-11-29
AMGEN INC. v. APOTEX INC.	2022-06-14

See all alemtuzumab litigation

PTAB Litigation

Petitioner	Date
Miltenyi Biomedicine GmbH et al.	2022-04-12
GEMoaB Monoclonals GmbH	2019-12-20
Forty Seven, Inc.	2018-01-08

See all alemtuzumab litigation

Pharmacology for alemtuzumab

Mechanism of Action	CD52-directed Antibody Interactions
Established Pharmacologic Class	CD52-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for alemtuzumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for alemtuzumab Derived from Company Disclosures

These patents were obtained from company disclosures

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	⤷ Try a Trial	2013-08-13	Company disclosures
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	⤷ Try a Trial	2013-08-13	Company disclosures
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	⤷ Try a Trial	2014-08-05	Company disclosures
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Patent No.	>Estimated Patent Expiration	>Source

3) Low Certainty: US Patents for alemtuzumab Derived from Patent Text Search

These patents were obtained by searching patent claims